These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3086853)

  • 1. The sustained release of LH X RH agonist from LH X RH agonist-polymer composite in patients with prostatic cancer.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetu I; Yamazaki I; Suzuki K
    Prostate; 1986; 8(4):325-32. PubMed ID: 3086853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of (D-Leu6)-des Gly-NH2 10-LHRH ethylamide against prostatic cancer.
    Yamanaka H; Makino T; Yajima H; Saruki K; Shida K
    Prostate; 1985; 6(1):27-34. PubMed ID: 3918298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
    Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
    J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer].
    Yamanaka H; Makino T; Kumasaka F; Shida K
    Hinyokika Kiyo; 1984 Apr; 30(4):545-60. PubMed ID: 6435416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
    Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
    Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.
    Rolandi E; Franceschini R; Giberti C; Brancadoro T; Martorana G; Barreca T
    Horm Res; 1988; 30(1):22-5. PubMed ID: 2975631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
    Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists].
    Isurugi K; Kondo Y; Hirasawa K; Oyamatsu T; Honma Y
    Nihon Hinyokika Gakkai Zasshi; 1989 Oct; 80(10):1466-73. PubMed ID: 2513445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testicular histology following chronic gonadotropin-releasing hormone agonist treatment.
    Rajfer J; Swerdloff RS; Heber DM
    Fertil Steril; 1984 Nov; 42(5):765-71. PubMed ID: 6436070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone-releasing hormone (LH-RH) analogs in treatment of prostatic cancer. Clinical perspective.
    Smith JA
    Urology; 1986 Jan; 27(1 Suppl):9-15. PubMed ID: 3079936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Oefelein MG; Cornum R
    J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Decapeptyl (D-Trp6-LH-RH) in the therapy of prostatic cancer with reference to the intramuscular administration of a depot preparation].
    Seppelt U; Bertermann H; Saerbeck C
    Urologe A; 1986 Sep; 25(5):298-301. PubMed ID: 2947371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
    Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
    Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of luteinizing hormone (LH) and follicle-stimulating hormone by (D-Leu6, des-Gly10-NH2)-LH-releasing hormone ethylamide after subcutaneous, intravaginal, and intrarectal administration to women.
    Saito M; Kumasaki T; Yaoi Y; Nishi N; Arimura A; Coy DH; Schally AV
    Fertil Steril; 1977 Mar; 28(3):240-5. PubMed ID: 320053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.